Prolonged IL-33/ST2 signalling may also contribute to poorer cardiac remodelling and promote heart failure following MI (27), despite augmenting ILC2-driven type 2 immune activity, which may be protective or reparative of ventricular function in the acute phase post-MI (57). This evidence concerns the gene IL33 and myocardial infarction.